Jun 042013
Colorado-based Clovis said in a statement today. The drug, CO-1686, is in the first of three phases of testing typically required before U.S. regulatory approval.
http://www.businessweek.com/news/2013-06-03/clovis-oncology-shares-almost-double-on-ovarian-drug-trial-data
by WORLD DRUG TRACKER
DR ANTHONY CRASTO
Sorry, the comment form is closed at this time.